Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Organogenesis Holdings Inc (ORGO)

Organogenesis Holdings Inc (ORGO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 399,809
  • Shares Outstanding, K 125,726
  • Annual Sales, $ 433,140 K
  • Annual Income, $ 4,950 K
  • EBIT $ -13 M
  • EBITDA $ 11 M
  • 60-Month Beta 1.73
  • Price/Sales 0.92
  • Price/Cash Flow 14.79
  • Price/Book 1.51

Options Overview Details

View History
  • Implied Volatility 175.80% ( -232.51%)
  • Historical Volatility 94.69%
  • IV Percentile 74%
  • IV Rank 37.44%
  • IV High 408.30% on 12/23/24
  • IV Low 36.62% on 05/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 45
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 631
  • Open Int (30-Day) 623

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.03
  • Number of Estimates 1
  • High Estimate -0.03
  • Low Estimate -0.03
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.02 +5.47%
on 12/23/24
4.14 -23.19%
on 11/25/24
-0.87 (-21.48%)
since 11/22/24
3-Month
2.75 +15.64%
on 11/04/24
4.57 -30.42%
on 11/13/24
+0.27 (+9.28%)
since 09/24/24
52-Week
2.16 +46.88%
on 04/25/24
4.70 -32.41%
on 01/08/24
-0.78 (-19.70%)
since 12/22/23

Most Recent Stories

More News
Insider Sale: President and CEO of $ORGO (ORGO) Sells 55,615 Shares

Gary S. Gillheeney, the President and CEO of $ORGO ($ORGO), sold 55,615 shares of the company on 12-13-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.8%...

ORGO : 3.18 (unch)
Insider Sale: President and CEO of $ORGO (ORGO) Sells 43,359 Shares

Gary S. Gillheeney, the President and CEO of $ORGO ($ORGO), sold 43,359 shares of the company on 12-12-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.4%...

ORGO : 3.18 (unch)
Insider Sale: President and CEO of $ORGO (ORGO) Sells 18,416 Shares

Gary S. Gillheeney, the President and CEO of $ORGO ($ORGO), sold 18,416 shares of the company on 12-06-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.5%...

ORGO : 3.18 (unch)
Organogenesis Holdings Inc. Expands Manufacturing Capacity with New Facility in Smithfield, Rhode Island

Organogenesis Holdings plans to expand with a new 122,000 sq. ft. biomanufacturing facility in Rhode Island.Quiver AI SummaryOrganogenesis Holdings Inc., a regenerative medicine company, announced plans...

ORGO : 3.18 (unch)
Organogenesis Expands Manufacturing Capacity to Support Future Growth

ORGO : 3.18 (unch)
Organogenesis Holdings Inc. Applauds CMS Decision on Coverage for Skin Substitute Products for Diabetic and Venous Ulcers

Organogenesis praises CMS decision allowing Medicare coverage for skin substitutes treating diabetic and venous ulcers starting February 2025.Quiver AI SummaryOrganogenesis Holdings Inc. has praised the...

ORGO : 3.18 (unch)
Organogenesis Commends Final LCDs

ORGO : 3.18 (unch)
Organogenesis (ORGO) Q3 2024 Earnings Call Transcript

ORGO earnings call for the period ending September 30, 2024.

ORGO : 3.18 (unch)
Organogenesis: Q3 Earnings Snapshot

Organogenesis: Q3 Earnings Snapshot

ORGO : 3.18 (unch)
Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results

ORGO : 3.18 (unch)

Business Summary

Organogenesis is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets.

See More

Key Turning Points

3rd Resistance Point 3.39
2nd Resistance Point 3.35
1st Resistance Point 3.26
Last Price 3.18
1st Support Level 3.13
2nd Support Level 3.09
3rd Support Level 3.00

See More

52-Week High 4.70
Fibonacci 61.8% 3.73
Fibonacci 50% 3.43
Last Price 3.18
Fibonacci 38.2% 3.14
52-Week Low 2.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar